- Home
- LGI vs DERM Comparison
LGI vs DERM Comparison
Compare LGI & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGI | DERM |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.3M | 267.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LGI | DERM |
|---|---|---|
| Price | $17.79 | $7.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | 63.9K | ★ 83.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,134,000.00 |
| Revenue This Year | N/A | $17.48 |
| Revenue Next Year | N/A | $55.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.95 | $5.06 |
| 52 Week High | $19.88 | $9.56 |
Technical Indicators
Market Signals| Indicator | LGI | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 30.96 | 43.92 |
| Support Level | $17.19 | $6.92 |
| Resistance Level | $17.75 | $7.96 |
| Average True Range (ATR) | 0.30 | 0.44 |
| MACD | -0.22 | -0.04 |
| Stochastic Oscillator | 4.82 | 16.46 |
Price Performance
Historical ComparisonAbout LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.